Biolinq is a digital health company developing a skin-applied, minimally-invasive electrochemical biosensor platform which analyzes biomarkers in the interstitial fluid to provide actionable health information. Given the platform potential of the technology and the unique ability to simultaneously measure multiple biomarkers, the company aims to develop a pipeline of biomonitoring products. Biolinq was founded in 2012 (as Electrozyme, LLC), and is located in San Diego.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 11/27/17 | $10,000,000 | Series A |
Grey Sky Venture Partners Hikma Ventures LifeSci Venture Partners M Ventures  Three Leaf Ventures | undisclosed |
| 03/28/19 | $4,750,000 | Series A |
Aphelion Capital JDRF T1D Fund LifeSci Venture Partners | undisclosed |
| 11/04/21 | $100,000,000 | Series B |
Aphelion Capital Ascensia Diabetes Care AXA IM Alts Broe Group Falcon Edge Capital Global Health Investment Fund Hikma Ventures Longevity Vision Fund M Ventures RiverVest Venture Partners Senvest Capital T&W Medical | undisclosed |
